ESMO Advanced Course on Cholangiocarcinoma 2024

ESMO Advanced Course on Cholangiocarcinoma 2024

Find ESMO On Social Media 






ESMO Advanced Course on Cholangiocarcinoma 2024

Health and Safety Policy

It is each participant’s responsibility to check and comply with the latest health and travel regulations to ensure a smooth and safe journey from the Country of origin to the event venue, and back. During the event, ESMO will apply health and safety protocols according to the latest local authority guidelines and regulations.

In general, ESMO recommends:

  • To apply health precautions and measures according to formal guidance and personal medical history

  • To stay up to date with the vaccination status

  • To perform a Rapid Antigen Test and wear a mask in case of symptoms

Hand sanitisers will be available throughout the venue; the use of mask is at own discretion in the absence of symptoms. Any changes to the ESMO health and safety protocols will be communicated on this webpage.

Travel Grant

In addition to the course registration and the hotel accommodation, a travel grant of maximum 600 euros is offered to selected applicants as a contribution versus their travel costs. The reimbursement will be processed after the course against original invoices/vouchers. Please be aware that visa costs are NOT covered by the travel grant and are the participant's responsibility.


Madrid, Spain

Registration Available

Application is via online form. During the application process you will be required to upload

your CV including a list of your publications

Applications for the course will close on 10 June 2024.

Programme Available

Learning objectives

  • To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma

  • To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma

  • To discuss the role of surgery and other locoregional therapy for cholangiocarcinoma

  • To investigate the role of immunotherapy for the management of cholangiocarcinoma

  • To explore currently available and novel targeted therapies and treatment options for advanced disease


  • Julien Edeline, France

  • Angela Lamarca, Spain

Related articles

More events

EHA Congress 2024

Thu, 13 Jun 2024 - Sun, 16 Jun 2024

Madrid, 28042
37th European Neurology Congress 2024

Thu, 13 Jun 2024 - Fri, 14 Jun 2024

Piazza John Kennedy 1
Roma, Lazio 00144
FIME 2024

Wed, 19 Jun 2024 - Fri, 21 Jun 2024

1901 Convention Center Drive
Miami Beach, FL 33139
United States
ESMO Gynaecological Cancers Congress 2024

Thu, 20 Jun 2024 - Sat, 22 Jun 2024

Piazza Indipendenza 4
Lugano, 6900